首页|卵巢癌患者新辅助化疗前后凝血功能变化及临床意义

卵巢癌患者新辅助化疗前后凝血功能变化及临床意义

扫码查看
目的 探讨卵巢癌患者新辅助化疗前后凝血功能、纤溶功能和血小板指标变化,并分析治疗前后相关指标与新辅助化疗(NACT)效果的风险关系。方法 纳入西安凤城医院 2020 年 3 月至 2023 年 3 月收治的卵巢癌患者为卵巢癌组,按 2∶1 比例选取同期女性体检者为对照组。比较两组凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、血小板体积分布宽度(PDW)、血小板压积(PCT)、血小板计数(PLT)、血小板平均体积(MPV)。比较NACT前后、不同临床分期NACT前后及不同疗效NACT前后上述指标变化情况。此外,根据治疗效果分为有效组和无效组。采用Logistic回归分析治疗前各参数与NACT疗效的关系;绘制受试者工作特征曲线分析治疗前各参数预测对NACT疗效预测价值。结果 研究共纳入患者 144 例。卵巢癌组 96 例,对照组 48 例。卵巢癌组FIB、PLT、MPV均高于对照组(P<0。05)。卵巢癌患者NACT后PT、TT、APTT、FIB、PLT均低于NACT前(P<0。05),且Ⅱ期患者NACT前后FIB、PLT低于Ⅲ期。有效组NACT前后PT、TT、APTT、FIB、PLT低于无效组,且两组NACT后PT、TT、APTT、FIB、PLT低于NACT前(P<0。05)。多因素Logistic回归分析提示,NACT前PT、TT、APTT、FIB、PLT过高是NACT无效的独立危险因素(P<0。05)。NACT前PT、TT、APTT、FIB、PLT预测NACT效果的曲线下面程分别为0。713(敏感度80。95%,特异度69。33%)、0。756(敏感度 71。43%,特异度 82。67%)、0。787(敏感度 76。19%,特异度 70。67%)、0。727(敏感度 71。43%,特异度 84。00%)、0。794(敏感度 80。95%,特异度 76。00%)。结论 卵巢癌患者NACT后凝血纤溶功能、血小板参数改变,且与临床分期、NACT效果存在关联,NACT前PT、TT、APTT、FIB、PLT过高是影响NACT效果的重要原因,基于上述 5 个参数构建卵巢癌患者NACT疗效风险预测模型,从而为临床提供参考。
Changes of coagulation function before and after neoadjuvant chemotherapy in patients with ovarian cancer and their clinical significance
Objective To investigate the changes of coagulation,fibrinolysis and platelet indexes in ovarian cancer patients before and after neoadjuvant chemotherapy,and to analyze the risk relationship between relevant indexes before treatment and the effect of neoadjuvant chemotherapy(NACT).Methods Patients with ovarian cancer admitted to Xi'an Fengcheng Hospital,from March 2020 to March 2023 were included as the ovarian cancer group,and female patients who underwent physical examination in the same period were selected as the control group according to a 2∶1 ratio.Prothrombin time(PT),thrombin time(TT),activated partial thromboplastin time(APTT),fibrinogen(FIB),platelet distribution width(PDW),platelet hematocrit(PCT),platelet(PLT)and mean platelet volume(MPV)were compared between the two groups.The changes of these indexes were compared before and after NACT,at different clinical stages and before and after NACT with different efficacy effects.Moreover,they were divided into effective and ineffective groups according to their treatment efficacy.Logistic regression was used to explore the relationship between the parameters and NACT efficacy;receiver operating characteristic curve was drawn to predict the value of NACT efficacy.Results A total of 144 patients were included,with 96 cases in the ovarian cancer group and 48 in the control group.The FIB,PLT and MPV of patients in the ovarian cancer group were higher than those in the control group(P<0.05).The PT,TT,APTT,FIB and PLT of ovarian cancer patients after NACT were lower than those before NACT(P<0.05).FIB and PLT of stage Ⅱ patients were lower than those of stage Ⅲ before and after NACT,and the PT,TT,APTT,FIB and PLT of the effective group were lower than those of the ineffective group before and after NACT,and the PT,TT,APTT,FIB and PLT of the two groups after NACT were lower than those before NACT(P<0.05).Multivariate Logistic regression analysis indicated that high PT,TT,APTT,FIB and PLT before NACT were independent risk factors for NACT ineffectiveness(P<0.05).The area under the curve of PT,TT,APTT,FIB and PLT before NACT to predict the effect of NACT were 0.713(sensitivity of 80.95%,specificity of 69.33%),0.756(sensitivity of 71.43%,specificity of 82.67%)and 0.787(sensitivity of 76.19%,specificity of 70.67%),0.727(sensitivity of 71.43%,specificity of 84.00%),0.794(sensitivity of 80.95%,specificity of 76.00%),respectively.Conclusion Changes in coagulation and fibrinolytic function and platelet parameters in ovarian cancer patients after NACT are associated with clinical stages and NACT effect.High levels of PT,TT,APTT,FIB and PLT before NACT are important reasons affecting NACT effect.Constructing the risk prediction model of NACT efficacy in ovarian cancer patients based on the above five parameters can provide a reference for clinical practice.

Ovarian cancerNeoadjuvant chemotherapyCoagulation functionPlatelets countEffect

师婉、杨亚兴、陈楚、王苗、王永锋、魏欣、雷芳

展开 >

西安凤城医院检验科(西安 710016)

西安凤城医院泌尿外科(西安 710016)

陕西省中医医院检验科(西安 710003)

卵巢癌 新辅助化疗 凝血功能 血小板计数 效果

2024

中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
年,卷(期):2024.27(5)
  • 23